In the 2010s, my business partner Doug joined two companies as CEO…both exactly twelve months AFTER they were acquired by PE firms.
In both cases, the story was the same.
Each company had shown strong historical growth. They had solid pipelines and capable leadership. The PE diligence process didn’t surface any major red flags. The deals closed with confidence.
And by the time Doug walked in the door a year later, both companies were significantly behind the growth forecasts that justified the acquisition price.
So what happened?
Did the PE firm fail in their diligence?
Did the company just fail to execute on what should have been a straightforward plan?
The answer, in both cases, was neither.
What got missed wasn’t visible in the numbers. It was buried in the structure underneath them.
The False Sense of Security in the Numbers
Here’s the uncomfortable truth about diligence: past performance does not guarantee future results.
Everyone knows this. It’s in every disclaimer, every caveat, every risk section.
And yet, when the numbers look good, it’s easy to assume the pattern will continue.
Revenue trending up? Pipeline coverage strong? CAC/LTV ratio healthy? Customer logos recognizable?
The math checks out. The story makes sense. The deal moves forward.
But numbers only tell you what happened. They don’t tell you why it happened, or whether the conditions that produced those results are stable, repeatable, and ready to scale under new ownership.
Did they hit their sales targets because the founder sold into their personal network?
Did growth come from landing one or two whales that aren’t repeatable?
Is the GTM motion actually a system, or is it held together by a few key people who know how to navigate around the gaps?
The numbers won’t tell you that.
And in most diligence processes, no one is set up to ask.
What “Looking Under the Hood” Actually Means
Every PE firm reviews GTM performance during diligence.
They look at pipeline coverage, sales capacity, marketing spend, customer acquisition metrics, and churn rates. They interview the CEO and the head of sales. They stress-test the growth assumptions.
This is smart, necessary work. And it’s not enough.
Because what gets reviewed are the outputs of the GTM engine…the speed and velocity metrics that show the machine is moving.
What rarely gets diagnosed is what’s under the hood…the structural integrity that determines whether the engine will hold up when you press harder on the accelerator.
Structural questions don’t live inside a single function. They connect across them. They sound like this:
- Pipeline coverage looks healthy, but deals are stalling in mid-funnel. Is that a sales execution problem, or is positioning fragmenting when reps try to adapt it for different buyer types because the ICP was never validated against actual win/loss data?
- Churn is elevated, and there’s a plan to address it. But is churn actually a retention problem, or did a loosely defined ICP allow wrong-fit customers into the pipeline, where they closed because sales hit quota but were never going to renew?
- Marketing is generating leads, but sales says they’re low quality. Is that a handoff problem, or is it that neither team is working from the same definition of who they’re actually trying to reach?
- The product team is shipping faster than revenue is growing. Is that a GTM execution gap, or is the product evolving faster than anyone can articulate its value, fragmenting the narrative that marketing, sales, and customer success all depend on?
- Leadership says they’re aligned on strategy, but every function is optimizing for different metrics. Is that an accountability problem, or is it that no documented strategy exists to align against, so each team built their own definition of success?
These aren’t single-function questions. They’re structural dependency questions.
And the reason they don’t get asked isn’t because PE firms don’t care. It’s because answering them requires a level of cross-functional visibility that most diligence processes aren’t designed to provide. Historically, uncovering that level of structural detail would extend timelines in ways that could kill deals.
Why This Gap Exists (And Why It’s Not Anyone’s Fault)
Most PE firms have talented operating partners and portfolio support teams.
These teams are excellent at what they do: driving value creation post-close, supporting portfolio company leadership, and identifying operational improvements.
But they’re also stretched thin across multiple companies, focused primarily post-acquisition, and working without diagnostic frameworks purpose-built to surface structural GTM issues in a compressed diligence timeline.
This isn’t a capability problem. It’s a tools problem.
Until now, there hasn’t been a way to quickly and rigorously diagnose the foundational structure of a GTM engine the way you can audit financials or assess product-market fit.
So the gap stays invisible. Not because anyone is cutting corners, but because the work required to see it doesn’t fit neatly into existing diligence processes.
The assumption becomes: we’ll figure it out post-close if something’s off.
And by the time “something’s off” becomes obvious, you’re 12 to 18 months in and trying to course-correct under board pressure with a team that’s already lost confidence.
What Happens When Structure Isn’t Diagnosed
Here’s what this looks like in practice.
A PE firm acquires a B2B software company. Historical growth is strong. Pipeline coverage is solid, anchored by recognizable customer logos. Churn is elevated, but there’s a plan to address it. The product team is capable and shipping regularly.
Diligence uncovers no major concerns. The deal closes.
Post-close, the product continues to evolve. New features, new modules, expanded capabilities. The offering gets broader and more powerful.
But no one maintains a coherent narrative as the product expands.
Marketing starts targeting adjacent segments without clear prioritization. Sales adapts messaging on the fly to fit different buyer types. The ICP drifts. No one notices because pipeline coverage still looks reasonable.
But deals start taking longer. Conversion rates drop. Churn stays stubbornly high despite the new customer success leader’s efforts.
Twelve months in, the company misses its growth targets.
The PE firm steps in. New CEO. New VP of Sales. Operational reviews. Another leadership change. Cost reductions.
Nothing fundamentally improves.
Years later, they’re still trying to figure out what’s broken.
The issue wasn’t effort, talent, or market conditions.
The issue was structural: the GTM foundation was never as solid as the numbers suggested. As the product evolved, that weakness became impossible to hide. GTM execution fragmented because no one knew what they were optimizing for anymore.
Every intervention treated symptoms (slow pipeline, weak conversion, high churn) without ever diagnosing the root cause.
This is the answer to the question I opened with: What got missed?
Not effort. Not intent. Not even execution.
What got missed was the structure that should have been diagnosed before the deal ever closed.
What Changes When You Can See Structure, Not Just Metrics
The best outcomes happen when structural clarity comes early, during diligence or immediately post-close, when decisions still have leverage.
A structural GTM diagnostic is purpose-built to do what diligence timelines and single-function reviews can’t:
- Trace symptoms to root causes across functions, so you know whether slow pipeline is a sales problem, a positioning problem, or an ICP problem masquerading as both
- Surface the dependency chains between pillars, revealing which gaps must be solved first because every downstream investment depends on them
- Distinguish between problems that require immediate intervention and problems that resolve themselves once upstream blockers are addressed
- Identify where the company is actively spending money on tactics that structurally cannot succeed given current foundational gaps
- Give leadership and the board a shared diagnostic framework, so post-close conversations are grounded in root causes rather than competing interpretations of symptoms
The output isn’t a strategy deck. It’s clarity: what’s working, what’s broken, and what to prioritize in the first 90 days.
This is what Fathom360 was built to do.
It’s a forensic-grade diagnostic designed to run in a diligence-compatible timeframe—giving you structural visibility before capital is committed and expectations are locked in.
When firms get this right, the impact compounds:
- Faster ramps in the first 12–18 months because leadership knows what to focus on
- Better hiring decisions based on diagnosed gaps, not assumptions
- Fewer mid-flight strategy pivots that burn credibility and momentum
- Board conversations grounded in shared understanding, not competing narratives
Diagnosis doesn’t slow deals. It de-risks them.
The Question No One Asks (But Should)
Before you close your next growth-dependent deal, ask one question:
Do we know why these numbers happened, or are we assuming the pattern will continue?
If the company hit its targets because the founder sold into their network, that’s not a repeatable system.
If growth came from one or two large customers in a narrow segment, that’s not a scalable foundation.
If the GTM motion looks fine on the surface but runs on informal handoffs and heroic individual effort, it won’t survive transition or scale.
The numbers won’t tell you this. Structure will.
And until now, diagnosing structure at the speed diligence requires hasn’t been possible.
If growth is central to your investment thesis, structural clarity isn’t optional.
Let’s talk. Fathom360 helps PE firms see what the numbers can’t show—before assumptions become expensive surprises.
